The future in the management of patients with asymptomatic carotid artery stenosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paraskevas Kosmas I, Sultan Sherif A, Aburahma Ali F, Moore Wesley S, Blecha Matthew, Myrcha Piotr, Zeebregts Clark J, Blinc Ales, Davies Alun H, D'Oria Mario, Gargiulo Mauro, Poredos Pavel, Svetlikov Alexei, Perler Bruce A, Chaturvedi Seemant, Sufali Gemmi, Saba Luca, Eldrup-Jorgensen Jens, Lyden Sean P, Setacci Carlo, DI Lazzaro Vincenzo, Reiff Tilman, Sawicka Agnieszka, Liapis Christos D, Lanza Gaetano, Spinetti Gaia, Bruno Antonino, Nicolaides Andrew N, Thapar Ankur, Uyttenboogaart Maarten, Jawien Arkadiusz, Mikhailidis Dimitri P, Spinelli Francesco, Stilo Francesco, Musialek Piotr, Gurevich Victor, Silvestrini Mauro, Erben Young M, Schneider Peter A, Lip Gregory Y, White Christopher J, Dardik Alan, Meschia James F, Malas Mahmoud B, Gloviczki Peter, Schermerhorn Marc L, Mansilha Armando
Аннотация
EVIDENCE ACQUISITION: PubMed/MedLine was searched until December 31, 2024 for studies in English discussing emerging technological advances in the diagnosis and management of patients with AsxCS.
EVIDENCE SYNTHESIS: Several technological advances have recently been reported, among others, nanoplastics and microplastics, artificial intelligence and machine learning in predictive analytics for stroke prevention, digital twins for personalized monitoring, electronic tattoos for continuous non-invasive monitoring, stroke risk prediction through plaque morphology and late-phase contrast-enhanced ultrasound. A brief overview of each technological advance is presented and discussed.
CONCLUSIONS: The technological advances discussed in the present article will aid the early diagnosis of AsxCS as well as the individualized optimal management of patients with AsxCS.